Idiopathic infantile hypercalcemia with severe nephrocalcinosis, associated with CYP24A1 mutations: a case report
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Nephrocalcinosis often occurs in infants and is caused by excessive calcium or vitamin D supplementation, neonatal primary hyperparathyroidism, and genetic disorders. Idiopathic infantile hypercalcemia (IIH), a rare cause of nephrocalcinosis, results from genetic defects in CYP24A1 or SLC34A1. Mutations in CYP24A1, which encodes 25-hydroxyvitamin D 24-hydroxylase, disrupt active vitamin D degradation. IIH clinically manifests as failure to thrive and hypercalcemia within the first year of life and usually remits spontaneously. Herein, we present a case of IIH wih CYP24A1 mutations.An 11-month-old girl visited our hospital with incidental hypercalcemia. She showed failure to thrive, and her oral intake had decreased over time since the age of 6 months. Her initial serum parathyroid hormone level was low, 25-OH vitamin D and 1,25-OH vitamin D levels were normal, and renal ultrasonography showed bilateral nephrocalcinosis. Whole-exome sequencing revealed compound heterozygous variants in CYP24A1 (NM_000782.4:c.376C>T [p.Pro126Ser] and c.1310C>A [p.Pro437His]). Although her hypercalcemia and poor oral intake spontaneously resolved in approximately 8 months, we suggested that her nephrocalcinosis and renal function be regularly checked in consideration of potential asymptomatic renal damage. Hypercalcemia caused by IIH should be suspected in infants with severe nephrocalcinosis, especially when presenting with failure to thrive.
Abstract
Nephrocalcinosis often occurs in infants and is caused by excessive calcium or vitamin D supplementation, neonatal primary hyperparathyroidism, and genetic disorders. Idiopathic infantile hypercalcemia (IIH), a rare cause of nephrocalcinosis, results from genetic defects in CYP24A1 or SLC34A1. Mutations in CYP24A1, which encodes 25-hydroxyvitamin D 24-hydroxylase, disrupt active vitamin D degradation. IIH clinically manifests as failure to thrive and hypercalcemia within the first year of life and usually remits spontaneously. Herein, we present a case of IIH wih CYP24A1 mutations.An 11-month-old girl visited our hospital with incidental hypercalcemia. She showed failure to thrive, and her oral intake had decreased over time since the age of 6 months. Her initial serum parathyroid hormone level was low, 25-OH vitamin D and 1,25-OH vitamin D levels were normal, and renal ultrasonography showed bilateral nephrocalcinosis. Whole-exome sequencing revealed compound heterozygous variants in CYP24A1 (NM_000782.4:c.376C>T [p.Pro126Ser] and c.1310C>A [p.Pro437His]). Although her hypercalcemia and poor oral intake spontaneously resolved in approximately 8 months, we suggested that her nephrocalcinosis and renal function be regularly checked in consideration of potential asymptomatic renal damage. Hypercalcemia caused by IIH should be suspected in infants with severe nephrocalcinosis, especially when presenting with failure to thrive.
참고문헌 (15)
- "Nephrocalcinosis" (2021)[URL]
- Ronnefarth G, "Nephrocalcinosis in children : a retrospective survey", Pediatr Nephrol, 14, pp.1016~1021 (2000)
- Habbig S, "Nephrocalcinosis and urolithiasis in children", Kidney Int, 80, pp.1278~1291 (2011)
- Hoppe B, "Diagnostic examination of the child with urolithiasis or nephrocalcinosis", Pediatr Nephrol, 25, pp.403~413 (2010)
- Lietman SA, "Hypercalcemia in children and adolescents", Curr Opin Pediatr, 22, pp.508~515 (2010)
- De Paolis E, "CYP24A1 and SLC34A1 genetic defects associated with idiopathic infantile hypercalcemia : from genotype to phenotype", Clin Chem Lab Med, 57, pp.1650~1667 (2019)
- Schlingmann KP, "Mutations in CYP24A1 and idiopathic infantile hypercalcemia", N Engl J Med, 365, pp.410~421 (2011)
- Gil A, "Vitamin D : classic and novel actions", Ann Nutr Metab, 72, pp.87~95 (2018)
- Marks BE, "Idiopathic infantile hypercalcemia : case report and review of the literature", J Pediatr Endocrinol Metab, 29, pp.127~132 (2016)
- Janiec A, "Long-term outcome of the survivors of infantile hypercalcaemia with CYP24A1 and SLC34A1 mutations", Nephrol Dial Transplant, 36, pp.1484~1492 (2021)
- Vogiatzi MG, "Vitamin D supplementation and risk of toxicity in pediatrics : a review of current literature", J Clin Endocrinol Metab, 99, pp.1132~1141 (2014)
- Seok Jin Kang, "Infantile hypercalcemia with novel compound heterozygous mutation in SLC34A1 encoding renal sodium-phosphate cotransporter 2a: a case report", Annals of Pediatric Endocrinology & Metabolism, 24(1), pp.64~67 (2019), 대한소아내분비학회
- Lee GM, "A novel variant of SLC34A1gene in an infant with idiopathic infantile hypercalcemia", ESPE Abstr, 89, pp.P2~P047 (2018)
- Barnett ML, "Hypercalcemia", Semin Oncol Nurs, 15, pp.190~201 (1999)
- Moza D, "Hypercalcemia and upper GI symptoms", Can J Gen Int Med, 13, pp.51~52 (2018)